 International Business Times [1] |
MannKind Moves Forward on Trials for Inhaled Insulin Treatment [2]
Minyanville.com The company will study patients with type 2 diabetes in one trial and type 1 in the other. Type 2 diabetes is the most common and fastest-growing form of the disease and is blamed in part on the obesity epidemic in the US. Type 1 is often diagnosed in … MannKind shares soar after FDA clears trial for insulin drug [3]Ct Post MannKind Confirms Design of Pivotal Studies [4]MarketWatch (press release) MannKind finalizes design for insulin therapy trials [5]Pharmaceutical Business Review Pharma Times [6] all 33 news articles » [7] |
More details can be found at www.diabeteshowto.com [8]